Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SLRX | US
-0.19
-9.45%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.82
1.93
1.96
1.71
Salarius Pharmaceuticals Inc. a clinical-stage biotechnology company focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577) a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors as well as Ewing sarcoma. The company also offers SP-3164 a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals Inc. is headquartered in Houston Texas.
View LessValue Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
139.3%1 month
116.4%3 months
233.9%6 months
200.6%-
-
1.12
-
-
1.52
0.14
-
-6.73M
2.62M
2.62M
-
-
-
-100.00
-119.83
0.23
1.05
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.09
Range1M
1.09
Range3M
5.94
Rel. volume
0.30
Price X volume
500.15K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ensysce Biosciences Inc | ENSC | Biotechnology | 0.206 | 2.86M | 15.86% | n/a | 24.79% |
Cyclacel Pharmaceuticals Inc | CYCC | Biotechnology | 1.32 | 2.84M | 15.79% | n/a | 0.50% |
Phio Pharmaceuticals Corp | PHIO | Biotechnology | 3.18 | 2.74M | 9.28% | n/a | 0.00% |
ZVSA | ZVSA | Biotechnology | 2.3 | 2.47M | 0.00% | 0.00 | 0.00% |
Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.56 | 2.36M | -3.11% | n/a | 0.00% |
Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.63 | 2.30M | -5.78% | n/a | 6.68% |
Altamira Therapeutics Ltd. | CYTO | Biotechnology | 0.5751 | 2.17M | -2.53% | 0.32 | 1.54% |
60 Degrees Pharmaceuticals Inc. Common Stock | SXTP | Biotechnology | 1.07 | 1.99M | -1.83% | n/a | 5.19% |
Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.003 | 1.90M | 11.11% | n/a | -101.21% |
Panbela Therapeutics Inc | PBLA | Biotechnology | 0.3354 | 1.76M | 5.14% | 0.00 | -39.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.52 | 0.53 | Expensive |
Ent. to Revenue | 0.14 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 1.12 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 233.89 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 2.62M | 3.66B | Emerging |